Skip to main content

"The Viral Hypothesis of Alzheimer's Disease: Time to put it to the test!" by Steven P. LaRosa, M.D.


Alzheimer’s disease (AD) was estimated to affect 35.5 million people worldwide in 2010 and is expected to affect 115.4 million people by 2050. Approximately 10% of people over 65 are affected and 50% of population > 85 are affected. The currently approved drugs provide minimal benefit. The benefit of experimental drugs observed in Phase II clinical trials has been followed by resounding failures in adequately powered Phase III clinical trials. Even the results of the highly publicized Biogen study have significant questions associated with it. It is quite clear that a new strategy must be entertained and tested.

Four members of the Human Herpes Virus family have been associated with development of Alzheimer’s disease; HSV-1, VZV, HHV-6A, and HHV-7. HSV-1 is capable in vitro leading to the production the Beta amyloid protein found in senile plaques and phosphorylating tau protein seen in neurofibrillary tangles seen in Alzheimer’s, a  phenomenon that can be blocked by co-incubating with acyclovir. Studies by Eimer et al in 5XFAD mice which hyperproduce Beta amyloid indicate that amyloid is elaborated rapidly following challenge with HSV-1 and is protective. This finding would indicate that amyloid is performing appropriately as an ancient immune protein to control infection and that repeated HSV-1 exposure may be the fuel to the amyloid build-up of Alzheimer’s.  Indeed, reactivation of HSV-1 infection as indicated by the presence of HSV-IgM antibodies in the setting of HSV IgG seropositivity has been associated with a 2-2.5X increase in Alzheimer’s disease. A recent retrospective study from the Taiwan National Health Insurance database compared 8362 patients greater than 50 with newly diagnosed HSV-1 infection to 25,086 sex and age- matched controls. HSV infection was associated with a 2.5 fold increased risk of dementia. A 90% reduction in the development of dementia was observed in the 7215 patients with new HSV infection who received anti-herpetic agents compared to the 1147 patients with new HSV infection who did not receive treatment. Similar but less dramatic findings were observed in individuals >50 with zoster (VZV), where infection was associated with a hazard ratio of 1.1 and treatment with an anti-herpetic medication was associated with a 45% reduction in the development of dementia (both statistically significant).

HHV-6A and HHV-7, which infect over 90% of humans over a lifetime, have recently been associated with Alzheimer’s disease. In the study by Eimer and colleagues HHV-6A exposure led to elaboration of Beta amyloid within 48 hours in 3D neuronal cell cultures. Fibrillization around the virus occurred with prevention of infection. In a study by Readhead and colleagues looking at brain samples from 3 independent cohorts, HHV-6A and HHV-7 were found in increased abundance in Alzheimer’s brains. This was not the case in other causes of neurodegeneration. Specific HHV-7 and HHV-6A gene regions were associated with Clinical Dementia Rating score and plaque density. Additionally, HHV-6A was associated with regulation of genes involved in processing of amyloid precursor proteins. Finally, HHV-6A levels had a negative correlation with neuronal cell fraction.

 Given the prevalence of infection with Human Herpes viruses in the population, an attempt must be made to explain the discordance with the number of Alzheimer’s disease cases. The most likely explanations involve host-genetics and host –pathogen interactions. Other than age the major risk factor for Alzheimer’s disease is the presence of Apolipoprotein E allele epsilon4 (ApoEe4). Humans can have zero, one or two copies of ApoEe4. Approximately 10% of the population is homozygous for APOEe4 with a 12X increased risk for AD while 49% are heterozygous associated with a 2-3X increased risk of AD. In one study the presence of a least one allele for ApoEe4 allele and HSV seropositivity was associated with AD in brain samples but not either factor alone. In an acute mouse infection model ApoEe4 homozygous mice had 13.6X higher levels of brain HSV-1 DNA compared with knockout mice. Similarly, the more ApoEe4 copies, the more AD in humans, and the more HHV-6A/B particles are found in the human brain. Additional genes that are associated with both risk of AD and susceptibility to viral infections include PILRA and ITGB3.

So what would be the next steps in testing the viral hypothesis of Alzheimer’s disease? To move from association to causality a randomized, placebo controlled trial of anti-viral in patients with early Alzheimer’s disease would need to be performed. The only agent with anti-viral activity against HHV-6A and HHV-7 in addition to HSV-1 and VZV is the experimental EPB-348 (Valomaciclovir). Based on the above data subjects would be included if they have evidence of HSV-reactivation (HSV-IgM seropositivity). The population could be enriched with those with at least one ApoEe4 allele or subgroup analysis could be performed in genetic traits associated with AD and viral infection to search for differential response to therapy. Patients would be followed out 78 weeks to look for a clinically meaningful slower decline in a measure of cognition and function such as the CDR-sum of boxes score.

Comments

  1. The controversial history of HHV-6 research is discussed in "The Chronic Fatigue Syndrome Epidemic Cover-up," a bestselling book on Amazon at www.cfsbook.com

    ReplyDelete
  2. I'M TOTALLY FREE FROM HERPES VIRUS
    Herpes is a serious and recurring condition that cannot be cured by drugs or injections by USA Doctors. But the best way to fight and get rid of  herpes virus permanently is to take natural herbal remedies, I red about DR JAMES, the great herbal Doctor, who cures people of HIV virus with his powerful herbal medicine. I contacted him to find out how he could help me and he told me never to be worried that he would help me with the natural herbs medicine! After 2 days of contacting him he told me the medicine is ready and he sent it to me via DHL COURIER SERVICE and it got me in 3 days! I used the medication as he prescribed for me (MORNING and EVENING) and I was cured! It's really like a dream, but I'm so happy! For people suffering from the following diseases Alzheimer disease, Eczema,Shingles,MS,Bullous Pemphigoid,Diabetes, cancer,Pcos, hypothyroidism,vaginal rashes, Herpes, COPD, HIV, arthritis, Hpv, liver disease, autoimmune diseases, Parkinson's disease, Lupus and more should contact him for his herbal medicine, because I am a living witness and I was cured of herpes virus. and DR James medicine is legitimate. I sent him what he asked for and he sent me his medication which I took for 2 weeks and today I am here with a negative result. When I went for the test, I was so happy after I took his herbal mix medicine.CONTACT DR JAMES FOR A PERMANENT CURE Email: drjamesherbalmix@gmail.com
    He's a good man and he will help you

    ReplyDelete

Post a Comment

Popular posts from this blog

"I'm Throwing you (ID) Pearls Here" by Steven P. LaRosa, M.D.

Prior to me employed by a non-academic teaching hospital I spent 11 years teaching Infectious Disease to medical students, Internal Medicine residents and ID fellows at 3 different academic teaching hospitals. I had a vast array of clinical pearls that I would share on teaching rounds. In my last 5 years in a non-teaching setting I am often amazed that no one ever taught physicians who are Board Certified in Internal Medicine these important teaching points. I thought it might be useful to share some of my favorite ID teaching points or "pearls" in this blog. 1) oral Beta lactam agents are not adequate treatment of bacteremia 2) Beta-lactam- beta lactamase drugs (Unasyn, Zosyn) and Carbapenems (Ertapenem and Meropenem) have perfectly adequate anaerobic coverage and do not require the addition of Metronidazole 3) Oral vancomycin has no bioavailability 4) Vancomycin is inferior to Beta lactam drugs for the treatment of serious MSSA infections 5) When awaiting sensiti

Opening One’s Mind to Lyme Disease Treatment (at least to need for more clinical trials)

Recently I was contacted and interviewed by a party to get my feelings about the state of treatment of Lyme disease. On the phone we lamented about the sizable number of poor souls who continue to suffer symptoms after what is considered standard of care treatment. I made it clear to the interviewer that I practice only evidence-based medicine and that I treat patients based upon the IDSA guidelines. I also railed against physicians who treat patients with months of parenteral antibiotic therapy for “Chronic Limes’ Disease” (ha ha). I stated fairly aggressive and believe that such practices opens the patient to life threatening infections including catheter-related bacteremia and Clostridium difficile colitis. After I got off the phone I started to do some soul searching. I have gotten so used to saying the same lines over and over again, but when was the last time that I actually had looked at the literature? The answer obviously was way too long ago. I was able to

Steven P. LaRosa, MD CV

  CURRICULUM VITAE Steven P. LaRosa, M.D. Address                       23 Junction Lane South Hamilton, MA 01982 Phone                          (401) 575-1812 Email                          slarosamd@gmail.com THERAPEUTIC AREAS Infectious Diseases Pulmonary/ Critical Care Coagulation Inflammation/Immunology Extracorporeal Devices RESEARCH EXPERIENCE Vice President, Clinical Development     Entasis Therapeutics, Mar 2020- present §   Medical lead- Phase III trial of Sulbactam-Durlobactam in Carbapem-Resistant Acinetobacter baumannii infections §   Safety Monitor- Phase III trial of Sulbactam-Durlobactam in Carbapenem-Resistant Acinetobacter baumannii infections §   Medical Lead- Phase III trial of Zoliflodacin in Gonorrhea §   Responsible for clinical development of ETX0282CPDP in cUTIs §   Responsible for clinical development of ETX0462 for Pseudomonas aeruginosa §   Interactions with BARDA/DTRA/Batelle for biodefense applications of ETX0462 §   Me